$VOGX

Vogenx (NASDAQ:VOGX) initiated a Phase 2b trial for mizagliflozin, a treatment for post-bariatric hypoglycemia (PBH), a condition with no FDA-approved therapies. The EMERGE trial will enroll 36 adults, testing 5 mg and 10 mg doses against placebo. Mizagliflozin aims to reduce hypoglycemic events by delaying glucose absorption in the small intestine. Vogenx's CEO and CSO highlighted the trial's significance and the drug's potential.

Vogenx appointed Richard Gorman as Chief Commercial Officer, effective October 12, 2026. Gorman resigned from the board and all committees. The company stated the change was not due to any disagreement. No replacement was disclosed. According to the SEC filing, this change is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Vogenx, Inc. (VOGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer Thirty-year biopharmaceutical commercial leader transitions from the Board of Direc

Vogenx, Inc. (VOGX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Ken Toombs to Board of Directors Former Chief Executive Officer of PA Consulting brings three decades of global professional services and l

Several biotech stocks reached 52-week highs on September 18, 2026. Vogenx (VOGX) shares surged to $38.41, driven by positive clinical trial results. HeartSciences (HSCS) rose 7% to $5.21, while HeartFlow (HTFL) increased 2% to $52.22. Freenome (FRNM) gained 5% to $17.25, and Halozyme (HALO) hit $112.66 after announcing a $1.3B offering.

William Wilkison reportedly owns 1.8 million shares of Vanguard Extended Duration Treasury ETF (VOGX), valued at $56.6 million. No insider trades have been filed by Wilkison in VOGX since 2021, according to SEC filings.

Vogenx, Inc. (VOGX) closed its initial public offering of 6.25 million shares at $13.00 per share, raising approximately $81.3 million before expenses. The biopharmaceutical company focuses on treatments for metabolic dysfunctions, including post-bariatric hypoglycemia and gastroparesis.

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.

Vogenx, a clinical-stage biopharma, plans an IPO of 6.25M shares at $11–$13 each, aiming to raise $68M at midpoint. Funds will support mizagliflozin development and R&D. The company has no revenue and reported losses. Listing on Nasdaq under VOGX is pending SEC and exchange approval.

Vogenx completed its IPO, issuing 6,250,000 shares at $13.00 each, raising $81.25M. The underwriter exercised a 15% overallotment, adding 937,500 shares and $12.19M. Total proceeds reached $93.44M before expenses, with 7,187,500 shares issued.